EASIX-Med: Exploring the relationship between drug therapy and EASIX

EASIX-Med: Exploring the relationship between drug therapy and EASIX - EASIX-Med

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00040389

Enrollment

30000

Registered

2026-05-21

Start date

2026-05-11

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Elixhauser Comorbidity Index

Interventions

Group 1: The aim of this research project is to identify bidirectional associations between pharmacotherapy and the EASIX score. The focus here is on medications known to affect the endothelium and wh

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients who had at least one visit to a university outpatient clinic or an inpatient stay in a general ward with a digital medical record system in place, and who received at least one prescription for medication between March 1, 2023, and February 28, 2025.

Exclusion criteria

Exclusion criteria: None.

Design outcomes

Primary

Measure	Time frame
Drug-related factors are quantified based on their association with the EASIX score and using descriptive p-values. To this end, the effect of endothelial-modulating drugs on the EASIX is examined as a continuous variable, calculated using the formula EASIX = (LDH [U/L] * Creatinine [mg/dL]) / Platelets [10^9/L] at three time points: on admission, after 7 days, and at discharge. In addition, a combined index (ECO-I) is calculated on an exploratory basis, resulting from a weighted combination of log2-transformed CRP and log2-transformed EASIX. ECO-I is included as a continuous variable in the statistical models. The association of ECO-I with clinical endpoints is investigated in the same manner as EASIX. Furthermore, the influence of high and low EASIX scores—taking medications into account—on efficacy and adverse effects is analyzed. Furthermore, the study aims to explore the relationship between the score and the combined ECO-I index to patient-relevant clinical endpoints, including time to death or transfer to the intensive care unit (censored at discharge), length of hospital stay, and the occurrence of adverse event syndromes (e.g., renal dysfunction, delirium).	—

Measure

Time frame

Drug-related factors are quantified based on their association with the EASIX score and using descriptive p-values. To this end, the effect of endothelial-modulating drugs on the EASIX is examined as a continuous variable, calculated using the formula EASIX = (LDH [U/L] * Creatinine [mg/dL]) / Platelets [10^9/L] at three time points: on admission, after 7 days, and at discharge. In addition, a combined index (ECO-I) is calculated on an exploratory basis, resulting from a weighted combination of log2-transformed CRP and log2-transformed EASIX. ECO-I is included as a continuous variable in the statistical models. The association of ECO-I with clinical endpoints is investigated in the same manner as EASIX. Furthermore, the influence of high and low EASIX scores—taking medications into account—on efficacy and adverse effects is analyzed. Furthermore, the study aims to explore the relationship between the score and the combined ECO-I index to patient-relevant clinical endpoints, including time to death or transfer to the intensive care unit (censored at discharge), length of hospital stay, and the occurrence of adverse event syndromes (e.g., renal dysfunction, delirium).

—

Secondary

Measure	Time frame
not applicable.	—

Countries

Germany

Contacts

Public ContactHanna Seidling

Zentrum für Innere Medizin / Innere Medizin IX: Abteilung für Klinische Pharmakologie und Pharmakoepidemiologie

Hanna.Seidling@med.uni-heidelberg.de+49 6221 56 38736

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 11, 2026